帕纳替尼维持治疗后再次尝试停药在慢性期慢性髓性白血病中的研究
本研究探讨既往TKI停药失败后,经帕纳替尼(15 mg/日)维持治疗12个月能否实现无治疗缓解(TFR)。50例入组,41例进入停药,12个月TFR率为36.6%(90%CI 24.1-50.6)。首次停伊马替尼、初始TKI治疗更长和首次TFR更长是TFR有利因素。
要点
- 帕纳替尼维持后二次停药12个月TFR率为36.6%(90%CI 24.1-50.6)
- 首次停伊马替尼、初始TKI治疗更长、首次TFR更长与TFR有利相关
- 不良事件风险提示需谨慎选择患者
核心结论
- 帕纳替尼维持治疗后再次尝试TKI停药可在部分CML患者中实现TFR,但需注意不良事件风险并谨慎选择患者。
研究设计与样本
- 日本成人白血病研究组RE-STOP219研究,入组既往TKI停药后复发并重获MR4.5的CML-CP患者,接受帕纳替尼15 mg/日维持12个月后停药。
- 共50例入组,49例接受帕纳替尼,41例进入TKI停药;主要终点为12个月TFR比例。
主要发现
- 12个月TFR比例为36.6%(90%CI 24.1-50.6)。
- 单因素分析显示首次停伊马替尼、初始TKI治疗时间更长和首次TFR持续时间更长是TFR的有利因素。
关键数值与推荐
- MR4.5定义为BCR-ABL1转录本水平≤0.0032%(国际标准)。
- 丧失主要分子学反应(MMR)的患者恢复帕纳替尼或既往TKI治疗。
临床怎么用
- 对于既往TKI停药失败后重获MR4.5的CML-CP患者,可考虑帕纳替尼维持治疗后再次尝试停药,但需评估不良事件风险并筛选合适患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-free remission (TFR) is now a key goal for chronic-phase chronic myeloid leukaemia (CML-CP) after achievement of a prolonged deep molecular response. About half of these patients can remain in remission without treatment, whereas those who relapse must resume lifelong therapy. This study investigated whether patients who previously failed tyrosine kinase inhibitor discontinuation could achieve TFR after receiving ponatinib as maintenance therapy. Patients who had relapsed after prior tyrosine kinase inhibitor (TKI) discontinuation and subsequently regained molecular response 4.5 (MR4.5; defined as a BCR-ABL1 transcript level ≤0.0032% on the International Scale [IS]) were enrolled, switched to ponatinib (15 mg/day) for 12 months and those who maintained MR4.5 discontinued TKI therapy. The primary end-point was the proportion of patients with TFR at 12 months. Patients losing major molecular response (MMR) resumed ponatinib or their prior TKI. Of 50 enrolled patients, 49 received ponatinib and 41 proceeded to TKI discontinuation. At 12 months, the proportion of patients with TFR was 36.6% (90% confidence interval: 24.1-50.6). Univariate analysis identified favourable factors for TFR: first discontinuation of imatinib, longer initial TKI therapy and longer first TFR duration. In conclusion, ponatinib maintenance followed by a second attempt at TKI discontinuation may facilitate successful TFR in selected CML patients. However, the risk of adverse events highlights the need for careful patient selection.
引用
- Iriyama N, Takahashi N, Fujimaki K, et al. Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study. Br J Haematol. 2026. PMID: 42422985. doi:10.1111/bjh.70678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。